Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non-Current Assets (2020 - 2025)

Mirum Pharmaceuticals has reported Non-Current Assets over the past 6 years, most recently at $293.1 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $293.1 million for Q4 2025, up 5.45% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 1.36% YoY), and the annual figure for FY2025 was $293.1 million, up 5.45%.
  • Non-Current Assets for Q4 2025 was $293.1 million at Mirum Pharmaceuticals, up from $254.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for MIRM hit a ceiling of $293.1 million in Q4 2025 and a floor of $4.5 million in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $208.6 million (2022), compared with a mean of $186.6 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 2736.93% in 2021 and later tumbled 59.95% in 2023.
  • Mirum Pharmaceuticals' Non-Current Assets stood at $128.1 million in 2021, then rose by 27.04% to $162.7 million in 2022, then soared by 59.26% to $259.1 million in 2023, then increased by 7.29% to $278.0 million in 2024, then increased by 5.45% to $293.1 million in 2025.
  • The last three reported values for Non-Current Assets were $293.1 million (Q4 2025), $254.5 million (Q3 2025), and $272.4 million (Q2 2025) per Business Quant data.